LM-vesiturbiinin tuotteistaminen

Tämän työn tarkoituksena on kehittää LM-vesiturbiini tuotantoon soveltuvaksi, käytöltään pitkäikäiseksi ja helposti huollettavaksi tuotesarjaksi. Työn ohjaavana runkona on käytetty VDI-Richtlinie 2221: 'Kehitystyön ja konstruoinnin yleinen kulku', mukaista järjestelmää. Lisäksi on käytetty valmistuksellista modulointia tuotteen osien suunnittelussa. Erityisesti on huomioitu tuotteen koko elinkaaren aikaiset kustannukset (LCC) ja sen vaatimukset mitoitukseen. LM-vesiturbiinistaon kehitetty kolmen erikokoisen laitteiston tuotesarja. Tuoteperheen yksittäisistä sylinteriryhmistä voidaan koota joustavasti erikokoisia ja -tehoisia energiantuotantoyksiköitä, jotka soveltuvat käyttöön hyvin pieniinkin virtauksiin ja putouskorkeuksiin. Piensarjatuotantoon hyvin soveltuvat materiaalit on valittu silmälläpitäen mahdollisimman edullista kokonaiskustannusta. Kiertomäntä laitteiston toiminnan kannalta tärkeimpänä ja siten vaativimpana osana on edellyttänyt laserhitsausta ja -leikkausta sekä koekappaleiden valmistusta, joiden perusteellalopulliseen rakenteeseen on päädytty. Mitoitus perustuu perinteisiin lujuuslaskentamenetelmiin, joiden avulla eri osien kestävyys käyttöolosuhteissa on pyrittysaamaan luotettavaksi vähintään 20 vuoden kestoiälle ja väsymiskestävyyteen käytön aikaisissa vaihtelevissa olosuhteissa. Kiertomäntä on ns. kevytrakenne koostuen ohutlevykennorakenteesta ja täytteenä olevasta kompound-materiaalista.

Rapid detection of bacterial resistance to antibiotics using AFM cantilevers as nanomechanical sensors.

The widespread misuse of drugs has increased the number of multiresistant bacteria, and this means that tools that can rapidly detect and characterize bacterial response to antibiotics are much needed in the management of infections. Various techniques, such as the resazurin-reduction assays, the mycobacterial growth indicator tube or polymerase chain reaction-based methods, have been used to investigate bacterial metabolism and its response to drugs. However, many are relatively expensive or unable to distinguish between living and dead bacteria. Here we show that the fluctuations of highly sensitive atomic force microscope cantilevers can be used to detect low concentrations of bacteria, characterize their metabolism and quantitatively screen (within minutes) their response to antibiotics. We applied this methodology to Escherichia coli and Staphylococcus aureus, showing that live bacteria produced larger cantilever fluctuations than bacteria exposed to antibiotics. Our preliminary experiments suggest that the fluctuation is associated with bacterial metabolism.

Antixenosis of bean genotypes to Chrysodeixis includens (Lepidoptera: Noctuidae)

The objective of this work was to evaluate bean genotypes for resistance to soybean looper (Chrysodeixis includens). Initially, free-choice tests were carried out with 59 genotypes, divided into three groups according to leaf color intensity (dark green, light green, and medium green), in order to evaluate oviposition preference. Subsequently, 12 genotypes with high potential for resistance were selected, as well as two susceptible commercial standards. With these genotypes, new tests were performed for oviposition in a greenhouse, besides tests for attractiveness and consumption under laboratory conditions (26±2ºC, 65±10% RH, and 14 h light: 10 h dark photophase). In the no-choice test with adults, in the greenhouse, the 'IAC Jabola', Arcelina 1, 'IAC Boreal', 'Flor de Mayo', and 'IAC Formoso' genotypes were the least oviposited, showing antixenosis-type resistance for oviposition. In the free-choice test with larvae, Arcelina 4, 'BRS Horizonte', 'Pérola', H96A102-1-1-1-52, 'IAC Boreal', 'IAC Harmonia', and 'IAC Formoso' were the less consumed genotypes, which indicates antixenosis to feeding. In the no-choice test, all genotypes (except for 'IAPAR 57') expressed moderate levels of antixenosis to feeding against C. includens larvae.

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.

BACKGROUND: While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies. AIM: To evaluate the treatment response to rifaximin in IBS patients in a phase IV trial. METHODS: IBS patients underwent lactulose hydrogen breath testing (LHBT). LHBT-positive patients were treated with rifaximin for 14 days. Prior to treatment as well as at week 4 and 14 following the start of rifaximin treatment, patients completed a questionnaire assessing symptom severity on a Likert scale from 0 to 10. RESULTS: One hundred and six of 150 IBS patients (71%) were LHBT-positive and treated with rifaximin. As assessed at week 4 following commencement of the therapy, rifaximin provided significant improvement of the following IBS-associated symptoms: bloating (5.5±2.6 before the start of the treatment vs. 3.6±2.7 at week 4, P<0.001), flatulence (5.0±2.7 vs. 4.0±2.7, P=0.015), diarrhoea (2.9±2.4 vs. 2.0±2.4, P=0.005) and abdominal pain (4.8±2.7 vs. 3.3±2.5, P<0.001). Overall well-being also significantly improved (3.9 ± 2.4 vs. 2.7 ± 2.3, P < 0.001). Similar improvements in IBS symptoms were obtained at week 14. Eighty-six per cent of patients undergoing repetitive LHBT (55/64) tested negative at week 4. CONCLUSIONS: We found a high percentage of LHBT-positive IBS patients. IBS-associated symptoms (bloating, flatulence, diarrhoea, pain) were improved for a period of 3 months following 2 weeks of treatment with rifaximin. We conclude that rifaximin treatment alleviates symptoms in LHBT-positive IBS patients.

Prévention et prise en charge de la résistance antivirale dans l'hépatite B chronique [A primer on the management of antiviral resistance in chronic hepatitis B]

Treatment options for chronic hepatitis B have significantly expanded over the last decade. Six nucleoside or nucleotide analogs (NA) with activity against the hepatitis B virus are currently available. Prolonged NA treatment is required in many cases to maintain viral suppression, with an inherent risk of the development of antiviral resistance. The purpose of this concise review is to provide an introduction to the prevention, diagnosis and management of antiviral resistance in chronic hepatitis B.